Hosted on MSN1mon
4D Molecular price target lowered to $6 from $8 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the shares after the company announced a pipeline ...
ETF Daily News1mon
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $6.00 by Analysts at Morgan Stanley
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective trimmed by Morgan Stanley from $8.00 to $6.00 in a report published on Monday,Benzinga reports.The brokerage ...